{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:25:37Z","timestamp":1787865937756,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07832-3","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T23:37:07Z","timestamp":1774481827000},"page":"5384-5394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inter-center variability of dosimetry methodology and the impact on reported absorbed dose for [177Lu]Lu-PSMA-617 therapy"],"prefix":"10.1007","volume":"53","author":[{"given":"B. J. R.","family":"Timmermans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. M.","family":"Priv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hofferber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. W.","family":"Konijnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Flux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Heskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Nagarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. I.","family":"Gear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Jentzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M. B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"12","key":"7832_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"10459","key":"7832_CR2","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227\u201339.","journal-title":"Lancet"},{"issue":"13","key":"7832_CR3","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1158\/1078-0432.CCR-20-4298","volume":"27","author":"BM Prive","year":"2021","unstructured":"Prive BM, et al. Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. Clin Cancer Res. 2021;27(13):3595\u2013601.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"7832_CR4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad AA, et al. Sequential [(177)Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 2024;25(10):1267\u201376.","journal-title":"Lancet Oncol"},{"issue":"3","key":"7832_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","volume":"85","author":"RS Eapen","year":"2024","unstructured":"Eapen RS, et al. Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1\/2 Study. Eur Urol. 2024;85(3):217\u201326.","journal-title":"Eur Urol"},{"issue":"2","key":"7832_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.euo.2022.09.002","volume":"6","author":"S Golan","year":"2023","unstructured":"Golan S, et al. Neoadjuvant (177)Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial. Eur Urol Oncol. 2023;6(2):151\u20139.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"7832_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2967\/jnumed.123.265986","volume":"65","author":"L Steinhelfer","year":"2024","unstructured":"Steinhelfer L, et al. Long-Term Nephrotoxicity of (177)Lu-PSMA Radioligand Therapy. J Nucl Med. 2024;65(1):79\u201384.","journal-title":"J Nucl Med"},{"issue":"8","key":"7832_CR8","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.2967\/jnumed.124.267452","volume":"65","author":"Z Ells","year":"2024","unstructured":"Ells Z, et al. Dosimetry of [(177)Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis. J Nucl Med. 2024;65(8):1264\u201371.","journal-title":"J Nucl Med"},{"issue":"1","key":"7832_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17\u201329.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"7832_CR10","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","volume":"49","author":"A Sundlov","year":"2022","unstructured":"Sundlov A, et al. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based (177)Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022;49(11):3830\u201340.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7832_CR11","volume-title":"Code of Federal Regulations. Title 21, Part 312, \u00a7 312.23: Investigational new drug application","author":"US Food","year":"2026","unstructured":"Food US, Administration D. Code of Federal Regulations. Title 21, Part 312, \u00a7 312.23: Investigational new drug application. U.S. Food and Drug Administration: Silver Spring (MD); 2026."},{"key":"7832_CR12","volume-title":"Council Directive 2013\/59\/Euratom of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation","author":"Council of the European Union","year":"2013","unstructured":"Council of the European Union. Council Directive 2013\/59\/Euratom of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation. Official Journal of the European Union: Brussels; 2013."},{"issue":"2","key":"7832_CR13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s00259-021-05471-4","volume":"49","author":"SMB Peters","year":"2022","unstructured":"Peters SMB, et al. Intra-therapeutic dosimetry of [(177)Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. Eur J Nucl Med Mol Imaging. 2022;49(2):460\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7832_CR14","doi-asserted-by":"crossref","unstructured":"Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP, 2002. 32(3\u20134): pp. 5-265.","DOI":"10.1016\/S0146-6453(03)00002-2"},{"issue":"1","key":"7832_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2967\/jnmt.114.152678","volume":"43","author":"W Jentzen","year":"2015","unstructured":"Jentzen W. An improved iterative thresholding method to delineate PET volumes using the delineation-averaged signal instead of the enclosed maximum signal. J Nucl Med Technol. 2015;43(1):28\u201335.","journal-title":"J Nucl Med Technol"},{"key":"7832_CR16","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/ad5c36","author":"N Hammersen","year":"2024","unstructured":"Hammersen N, et al. Pet quantification performance of the oversize-volume-of-interest approach in the context of tumour dosimetry in radionuclide therapy planning. Phys Med Biol. 2024;69(16):165007. https:\/\/doi.org\/10.1088\/1361-6560\/ad5c36.","journal-title":"Phys Med Biol"},{"issue":"01","key":"7832_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1055\/s-0043-120726","volume":"41","author":"V Stebner","year":"2018","unstructured":"Stebner. V, et al. Quantitative PET-Bildgebung f\u00fcr die Dosimetrie an Beispielen von 124I, 86Y, 68Ga und 44Sc. Der Nuklearmediziner. 2018;41(01):37\u201351.","journal-title":"Der Nuklearmediziner"},{"issue":"1","key":"7832_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13550-023-00952-z","volume":"13","author":"SMB Peters","year":"2023","unstructured":"Peters SMB, et al. Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation. EJNMMI Res. 2023;13(1):6.","journal-title":"EJNMMI Res"},{"issue":"1","key":"7832_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40658-022-00512-9","volume":"9","author":"L Carnegie-Peake","year":"2022","unstructured":"Carnegie-Peake L, et al. Quantification and dosimetry of small volumes including associated uncertainty estimation. EJNMMI Phys. 2022;9(1):86.","journal-title":"EJNMMI Phys"},{"key":"7832_CR20","doi-asserted-by":"publisher","first-page":"103335","DOI":"10.1016\/j.ejmp.2024.103335","volume":"120","author":"S Curkic Kapidzic","year":"2024","unstructured":"Curkic Kapidzic S, et al. Kidney dosimetry in [(177)Lu]Lu-DOTA-TATE therapy based on multiple small VOIs. Phys Med. 2024;120:103335.","journal-title":"Phys Med"},{"issue":"13","key":"7832_CR21","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1007\/s00259-018-4136-7","volume":"45","author":"JI Gear","year":"2018","unstructured":"Gear JI, et al. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2018;45(13):2456\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7832_CR22","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. Olinda\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023\u20137.","journal-title":"J Nucl Med"},{"issue":"4","key":"7832_CR23","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00259-021-05538-2","volume":"49","author":"SMB Peters","year":"2022","unstructured":"Peters SMB, et al. [(68)Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [(177)Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging. 2022;49(4):1101\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"7832_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v028.i08","volume":"28","author":"T Hothorn","year":"2008","unstructured":"Hothorn T, et al. Implementing a Class of Permutation Tests: The coin Package. J Stat Softw. 2008;28(8):1\u201323.","journal-title":"J Stat Softw"},{"issue":"9","key":"7832_CR25","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, et al. Joint EANM\/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50(9):2830\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"7832_CR26","first-page":"S99","volume":"46","author":"R Barone","year":"2005","unstructured":"Barone R, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46(Suppl 1):S99\u2013106.","journal-title":"J Nucl Med"},{"issue":"1","key":"7832_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","volume":"21","author":"B Emami","year":"1991","unstructured":"Emami B, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"7832_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.zemedi.2023.01.007","volume":"34","author":"D Hardiansyah","year":"2024","unstructured":"Hardiansyah D, et al. Population-based model selection for an accurate estimation of time-integrated activity using non-linear mixed-effects modelling. Z Med Phys. 2024;34(3):419\u201327.","journal-title":"Z Med Phys"},{"issue":"7","key":"7832_CR29","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.2967\/jnumed.122.265094","volume":"64","author":"J Brosch-Lenz","year":"2023","unstructured":"Brosch-Lenz J, et al. An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 2: Overall Variabilities in Absorbed Dose. J Nucl Med. 2023;64(7):1109\u201316.","journal-title":"J Nucl Med"},{"issue":"8","key":"7832_CR30","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.2967\/jnumed.123.267293","volume":"65","author":"J Brosch-Lenz","year":"2024","unstructured":"Brosch-Lenz J, et al. An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 3: Contribution from Calculating Absorbed Dose from Time-Integrated Activity. J Nucl Med. 2024;65(8):1166\u201372.","journal-title":"J Nucl Med"},{"issue":"3","key":"7832_CR31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2967\/jnumed.124.268612","volume":"66","author":"S Kurkowska","year":"2025","unstructured":"Kurkowska S, et al. An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 4: Impact of Fitting Functions in Estimated Absorbed Doses. J Nucl Med. 2025;66(3):441\u20138.","journal-title":"J Nucl Med"},{"issue":"Suppl 3","key":"7832_CR32","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.2967\/jnumed.121.262748","volume":"62","author":"C Uribe","year":"2021","unstructured":"Uribe C, et al. An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 1: Design and Early Results of the SNMMI Dosimetry Challenge. J Nucl Med. 2021;62(Suppl 3):S36\u201347.","journal-title":"J Nucl Med"},{"issue":"1","key":"7832_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40658-020-00328-5","volume":"7","author":"D Finocchiaro","year":"2020","unstructured":"Finocchiaro D, et al. Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy. EJNMMI Phys. 2020;7(1):63.","journal-title":"EJNMMI Phys"},{"issue":"3","key":"7832_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/1754-9485.12462","volume":"60","author":"SK Vinod","year":"2016","unstructured":"Vinod SK, et al. A review of interventions to reduce inter-observer variability in volume delineation in radiation oncology. J Med Imaging Radiat Oncol. 2016;60(3):393\u2013406.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"1","key":"7832_CR35","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13014-020-01677-2","volume":"16","author":"J van der Veen","year":"2021","unstructured":"van der Veen J, et al. Interobserver variability in organ at risk delineation in head and neck cancer. Radiat Oncol. 2021;16(1):120.","journal-title":"Radiat Oncol"},{"issue":"3","key":"7832_CR36","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.semnuclmed.2025.03.005","volume":"55","author":"F Yang","year":"2025","unstructured":"Yang F, et al. AI in SPECT Imaging: Opportunities and Challenges. Semin Nucl Med. 2025;55(3):294\u2013312.","journal-title":"Semin Nucl Med"},{"key":"7832_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/mp.17684","author":"Z Lu","year":"2025","unstructured":"Lu Z, et al. Automatic bone marrow segmentation for precise [(177)Lu]Lu-PSMA-617 dosimetry. Med Phys. 2025;52(6):3970\u20132980. https:\/\/doi.org\/10.1002\/mp.17684.","journal-title":"Med Phys"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07832-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07832-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07832-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:47:24Z","timestamp":1782715644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07832-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7832"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07832-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Medical Review Ethics Committee Region Arnhem-Nijmegen and was registered on clinicaltrials.gov (NCT03828838). All subjects provided written informed consent before study entry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}